Ductal Carcinoma in Situ of the Breast
December 2019 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Ductal Carcinoma in Situ of the Breast abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Ductal Carcinoma in Situ of the Breast. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Ductal Carcinoma in Situ of the Breast. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Ductal Carcinoma in Situ of the Breast every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:The Assisi Think Tank Meeting Survey of post-mastectomy radiation therapy in ductal carcinoma in situ: Suggestions for routine practice.
Authors:Montero-Luis A, Aristei C, Meattini I, Arenas M, Boersma L, Bourgier C, Coles C, Cutuli B, Falcinelli L, Kaidar-Person O, Leonardi MC, Offersen B, Marazzi F, Rivera S, Tagliaferri L, Tombolini V, Vidali C, Valentini V, Poortmans P
Institution:Radiation Oncology, University Hospital HM Sanchinarro, Madrid, Spain. Electronic address: amontero@hmhospitales.com. Italy. Italy. Huis, Amsterdam, Netherlands. Cambridge, UK. Israel. Rome, Italy. Roma, Italy. Italy. (ASUITS), Trieste, Italy. Roma, Italy. Sciences & Lettres - PSL University; Paris, France.
Journal:Crit Rev Oncol Hematol. 2019 Jun;138:207-213. doi: 10.1016/j.critrevonc.2019.04.016. Epub 2019 Apr 20.

2:Minimally Invasive Intact Excision of High-Risk Breast Lesions and Small Breast Cancers: The Intact Percutaneous Excision (IPEX) Registry.
Authors:Whitworth P, Schonholz S, Phillips R, Robertson Y, Ruiz A, Winchester S, Graham C, Simpson J, Wernecke C
Institution:Nashville Breast Center, Nashville, TN, USA. patwhitworth@gmail.com.
Journal:Ann Surg Oncol. 2019 Apr;26(4):954-960. doi: 10.1245/s10434-019-07212-2. Epub 2019 Feb 12.

3:National consensus recommendations on patient-centered care for ductal carcinoma in situ.
Authors:Gagliardi AR, Wright FC, Look Hong NJ, Groot G, Helyer L, Meiers P, Quan ML, Urquhart R, Warburton R
Institution:Toronto General Hospital Research Institute, University Health Network, 200 Elizabeth Street, Toronto, M5G2C4, Canada. anna.gagliardi@uhnresearch.ca. Canada. Canada. Saskatoon, Canada. Hospital, Saskatoon, Canada. Calgary, Canada.
Journal:Breast Cancer Res Treat. 2019 Apr;174(3):561-570. doi: 10.1007/s10549-019-05132-z. Epub 2019 Jan 9.

4:Leveraging the variable natural history of ductal carcinoma in situ (DCIS) to select optimal therapy.
Authors:Rojas KE, Fortes TA, Borgen PI
Institution:Department of Surgery, Brooklyn Breast Cancer Program of Maimonides Medical Center, 745 64th Street, Brooklyn, NY, 11220, USA. kristinrojasmd@gmail.com.
Journal:Breast Cancer Res Treat. 2019 Apr;174(2):307-313. doi: 10.1007/s10549-018-05080-0. Epub 2018 Dec 8.

5:External accelerated partial breast irradiation for ductal carcinoma in situ: long-term follow-up from a phase 3 randomized trial.
Authors:Becherini C, Meattini I, Livi L, Garlatti P, Desideri I, Scotti V, Orzalesi L, Sanchez LJ, Bernini M, Casella D, Nesi S, Nori J, Bianchi S, Pallotta S, Marrazzo L
Institution:1 Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.; 2 Breast Surgery Unit, Oncology Department, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.; 3 Diagnostic Senology Unit, Oncology Department, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.; 4 Division of Pathological Anatomy, Oncology Department, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.; 5 Medical Physics Unit, Oncology Department, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
Journal:Tumori. 2019 Jun;105(3):205-209. doi: 10.1177/0300891618811278. Epub 2018 Nov 26.

6:Stromal characteristics are adequate prognosticators for recurrence risk in ductal carcinoma in situ of the breast.
Authors:Van Bockstal M, Lambein K, Smeets A, Slembrouck L, Neven P, Nevelsteen I, Weltens C, Van Limbergen E, Christiaens MR, Van Ongeval C, Wildiers H, Libbrecht L, Floris G
Institution:Department of Pathology, Erasmus MC, University Medical Center Rotterdam, P.O. Box 2040, 3000 CA, Rotterdam, the Netherlands; Laboratory of Experimental Cancer Research, Department of Radiation Oncology and Experimental Cancer Research, Ghent University, De Pintelaan 185, 9000 Ghent, Belgium. Electronic address: m.vanbockstal@erasmusmc.nl. Belgium; Department of Surgical Oncology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium. Leuven, Belgium. Belgium. Belgium; Department of Gynecology and Obstetrics, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium. Leuven, Belgium. 3000 Leuven, Belgium. 3000 Leuven, Belgium. Leuven, Belgium. Belgium. Leuven, Belgium. Sint-Lambrechts-Woluwe, Belgium. Belgium; Department of Imaging and Pathology, Laboratory of Translational Cell & Tissue Research, KUL University of Leuven, Herestraat 49, 3000 Leuven, Belgium.
Journal:Eur J Surg Oncol. 2019 Apr;45(4):550-559. doi: 10.1016/j.ejso.2018.11.005. Epub 2018 Nov 12.

For a FREE PREVIEW of the Medifocus Guidebook on Ductal Carcinoma in Situ of the Breast click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Ductal Carcinoma in Situ of the Breast click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Ductal Carcinoma in Situ of the Breast...
at a Special 20% Discount


Medifocus Guidebook on Ductal Carcinoma in Situ of the Breast

Updated: January 6, 2020
162 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Ductal Carcinoma in Situ of the Breast is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

DC83566398

Coupon Expires: February 22, 2020



What Our Customers Are Saying...

"The MediFocus Guidebook on DCIS was more than adequate for my research on this condition and I would recommend it to anyone wanting the "whole picture". Thank you for providing this excellent service."
C.M.
Los Angeles, California


"At a very difficult time, your MediFocus Guidebook on Ductal Carcinoma in Situ helped our family make informed decisions. Thank you for your help!"
M.A.L.
Metarie, Louisiana


"I was recently diagnosed with DCIS and was looking everywhere for information to get myself educated. The MediFocus Guidebook was very helpful in clarifying everything for me. The information is so well organized that it makes it easy to read and understand. I feel much better now that I've read this Guidebook and have a clearer understanding of the issues that I face. I highly recommend this Guidebook to anyone seeking to understand DCIS."
C.G.
Ft. Lauderdale, Florida



  
Medifocus Digest Alert is published by Medifocus, Inc.
3809 Clarks Lane, Suite 100, Baltimore, MD 21215 USA
Copyright © 2020 Medifocus, Inc. All rights reserved.